SUNNYVALE, Calif. , Oct. 23, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that its Board of Directors has taken steps to improve its corporate governance by unanimously approving the adoption of certain corporate governance best practices. Updated corporate governance can be viewed at http://www.amarantus.com/investor-relations/c...nance.html .

"Amarantus is at a critical stage in its development and the Board is taking the necessary steps to ensure that we enhance the shareholder value we have developed over the last few months," said Gerald E. Commissiong , President & CEO of Amarantus. "As we work towards critical milestones and begin to deliver new information about the status of our product candidates to the marketplace, we expect significant interest from groups in our industry. The Board's actions will ensure that we are prepared to deal with the tasks that lie before us as we seek to maximize shareholder value."